Anti-Microbial Agents: Anti-Bacterial Agents: Sulfonamides

Sara Rasoul-Amini, Pharm D, PhD in Medicinal Chemistry; Department of Medicinal Chemistry, School of Pharmacy, Shiraz University of Medical Sciences(SUMS), Oct 2024

SECTION 7 Drugs Impacting Infectious and Neoplastic Disease Processes

CHAPTER 29 (

Drugs Used to Treat Bacterial Infections

Elmer J. Gentry, E. Jeffrey North, and Robin M. Zavod

SaraRAmini Oct 2024

SECTION 7 Drugs Impacting Infectious and Neoplastic Disease Processes



Drugs Used to Treat Bacterial Infections

Elmer J. Gentry, E. Jeffrey North, and Robin M. Zavod

Drugs covered in this chapter^a:


ANTIBACTERIALS

Sulfonamide class

- Silver sulfadiazine
- Sulfacetamide
- Sulfamethoxazole
- Sulfisoxazole
- Trimethoprim


Sulfonamide


- Foundation
- Nomenclature
- Mechanism Of Action: MOA
- Structure Activity Relationship: SA
- Physicochemical properties
- Metabolism
- Sulfonamides in clinic




Foundation of Sulfonamides

• Prontosil rubrum: a red dye






- ✓ examined by Gerhard Domagk in Bayer Co., Germany
- ✓ believed to affect selectively on pathogenic bacteria
- ✓ works selectively like Gram Stain
- ✓ against streptococcal infections
- ✓ not effective in-vitro



Sulfanilamide


- ✓ As Prodrug: active metabolite: by liver reductase:
- ✓ identified as p-amino-benzene-sulfonic acid or sulfonamide:
- ✓ sulfanilamide: colourless

Foundation of Antimicrobial



Nomenclature of Sulfonamide Scaffold

- **Prontosil:** 4-[(2,4-Di-amino-phenyl)-azo]-benzene-sulfonamide:
- ✓ as a Pro-Drug to produce sulfanilamide scaffold



MOA for Sulfonamides

- Inhibitor of Dihydro-Pteroate synthase
 ✓ responsible enzyme in the biosynthesis of:
 folic acid (dihydro-folic acid) & ultimately thymine
- Competing with PABA at the active site of the enzyme
- Might work as anti-metabolite: false metabolite
- Pharmacophore portion: will be given in SAR
- Can be reversed by adding/ prescribing PABA
- Consider against intrinsically resistant bacteria

8






Figure 29.3 Microbial biosynthetic pathway leading to tetrahydrofolic acid synthesis and major site of action (\uparrow) of sulfonamides as well as site of action seen in some bacteria (\leftarrow) , resulting in incorporation of sulfanamide as a false metabolite.

Biosynthetic Site of Action for Sulfonamides



Comparing PABA versus Sulfonamides to Introduce SAR

- Compare distances of:
- \checkmark "O-O in COO & H-N4 to O-C" to "O-O in SOO & H-N4 to O-S"
- Compare pk_a of PABA & sulfonanilic acid & sulfonanilamide:
- ✓ pk_a for PABA = 4.9 pk_a for sulfanilic acid = 10.4
- ✓ pk_a for optimum sulfonamide as antibacterial agent = 6.1-7.4
- Compare target interactions for both



Comparing PABA versus Sulfonamides to Introduce SAR- Contd.

- Compare three target interactions for both:
- ✓ hydrogen bond through p-amino group
- ✓ Van Der waals interactions through aromatic ring
- \checkmark ionic bond through anionic carboxylate or sulfonamide





FIGURE 19.8 Sulphonamide prevents PABA from binding by mimicking PABA.

SaraRAmini Oct 2024




SAR for Sulfonamides

- 1. Chemistry scaffold: 4-amino-benzene sulfonamide
- 2. R1 & R1': provide appropriate pK_a to mimic PABA:
- H or cation salt which is in equilibrium with H in biologic media


&

- electron withdrawing hetero-aromatic azole (isoxazole / oxazole) or diazine (pyrimidine)
- 3. R4: H or must be metabolizable to H
- Overall, consider distance of N₄-H to oxygens in SO₂
- Characteristics to consider:
- ✓ pK_a: related to Electron Withdrawing Groups (EWG) as R1 & R1'
- ✓ water solubility: related to substitutes in R1 & R1'
- ✓ crystalluria: kidney damage: urine pH (about 6): pK_a related
- $\checkmark\,$ salt preparation: related to the acidity of acidic hydrogens: pK_a related




Pharmacokinetic for Sulfonamides

- GI absorption
- Distribution
- Protein Binding: PB: 30-70%
- Metabolism
- Excretion by kidney
- Plasma mediated resistance: ?




Metabolism for Sulfonamides

- Phase I: hydrolysis, ...
- ✓ N4-hydroxylation: hydroxyl amine ✓ N4-oxidation
- Phase II: conjugation including:
- ✓ N1-glucuronidation
- ✓ sulfonylation
- ✓ N1-acetylation
- ✓ N4-acetylation




SaraRAmini Oct 2024




Clinical Characteristics for Sulfonamides

- Bacteriostatic
- Broad spectrum
- Therapeutic usages:
- ✓ UTI
- ✓ otitis
- ✓ ulcerative colitis
- Side Effects
- Allergic to sulfa



Side Effects of Sulfonamides

• Rash, vomiting, nausea, ...



- Hematologic reactions: in G6PD deficient people
- Hypersensitivity reactions:
- ✓ Stevens Johnson syndrome
- ✓ photosensitivity
- Crystalluria: what is the solution?

Table 29.1 Clinically Relevent Sulfonamides

| Drug: Generic Name | Product | R | H ₂ N | R′ | рK _a |
|-----------------------------------|--|----------------------------------|------------------|------------------------|-------------------------|
| Sulfisoxazole acetyl (prodrug) | In combination with eryth- romycin ethylsuccinate | CH3 | | _с-сн₃ | 5.6 after hydrolysis |
| Sulfamethoxazole | In combination with trimethoprim | H ₃ C CH ₃ | | —н | 5.0 |
| Sulfadiazine | Oral dosage form | $\sim N_N$ | | —н | 6.52 |
| Silver sulfadiazine | Topical dosage form | $\sim N$ | | ⊖ _{Ag} ⊕ | |
| Sulfacetamide sodium | Opthalmic dosage form | — С-СН ₃ | | ⊖ ⊕ _{Na} ⊕ | 5.4 free acid |
| Sulfasalazine | Gastrointestinal oral dosage form | | | | |
| Cara D Amini Oct 2024 | | | | | |


SaraRAmini Oct 2024

Common Sulfonamides in Clinic

- Sulfacetamide
- Sulfisoxazole
- Silver sulfadiazine
- Sulfadoxine: single & in combinational dosage
- Sulfasalazine: conjugational dosage form
- Triple sulfa: combinational dosage form
- \checkmark what are the contents?
- Cotrimoxazole: combinational dosage form
- ✓ what are the contents?


Sodium Sulfacetamide

- Follow SAR in this structure
- $pK_a = 5.4$ in free acid
- Therapeutic usage: against ...
- Formulation: eye drop: ? %




Sulfisoxazole & Sulfisoxazole Acetyl

- Follow SAR in this structure.
- pK_a = 5.6 after hydrolysis (R1=H)



R1 = H; Acetyl (COCH₃)


• What is the commercial formulation?



SaraRAmini Oct 2024

Sulfamethoxazole: R = H

- Follow SAR in this structure.
- $pK_a = 5$



• What is the commercial formulation?


Sulfadiazine & Silver Sulfadiazine

H₂N

- Follow SAR in this structure.
- $pK_a = 6.52$



• Formulation: topical




N²

:0


HN

Synthesis of Sulfa-Pyrimidine Derivatives of Sulfonamides



Sulfadoxine


- Follow SAR in this structure.
- $pK_a = 6.16 + 0.5 = 5.66 6.66$



- What is the commercial formulation?
- ✓ single: not provided
- combinatorial dosage form: with pyrimethamine (DHFRI)

Sulfasalazine: Salicyl-azo-Sulfapyridine


- 2-hydroxy-5-{[4-(2-pyrdinyl-amino)-sulfonyl] phenyl]
- azo} Benzoic acid
- Follow SAR in this structure.
- pK_a = ?




- Find the correlation of "sal" in the generic name to its structure.
- Therapeutic usage: against ulcerative colitis
- Formulation: topical
- What is the commercial formulation?

Bio-Activation of Sulfasalazine

- As a prodrug:
- Introduce active metabolites.



Synthetic Pathway for Sulfasalazine



Investigational Drug: Succinyl Sulfathiazole

- As a developing derivative
- Advantages & applications: ?




FIGURE 1 Succinyl sulphathiazole is a prodrug of sulphathiazole.





FIGURE 2 Substitution on the aniline nitrogen with benzoyl groups.


SaraRAmini Oct 2024

To synthesize Various Sulfonamides




Most sulfonamides can be prepared by amine sulfonylation.

Synthetic pathway-1




SaraRAmini Oct 2024

Synthetic pathway-2



Synthetic pathway-3



Synthetic method for the synthesis of acylated sulfonamides